Ozempic diabetes competitor gets PBS knockback

Eli Lilly’s Mounjaro would need “substantial price reduction”, says PBAC Mounjaro, the type-2 diabetes medication that the New York Times recently predicted “’could overshadow Ozempic” has been refused funding via the Pharmaceutical Benefits Scheme (PBS). In the latest outcomes from the Pharmaceutical Benefits Advisory Committee’s July meeting, the body said it “did not recommend tirzepatide

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Pharmacy workers ‘betrayed and angry’
Next Research Roundup